Teprasiran

N/A

Report date: 2024/09/06 20:00:43
NME

Base Information

Drug NameTeprasiran
Drug Alias NameDGFiTeprasiran sodiumQPI-1002AKIi-5I-5NP +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionTumor protein p53 inhibitorsRNA interference
TargetsTumor protein p53
Therapy Area/IndicationsRejection of renal transplantationDelayed Graft FunctionHeart Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSilence TherapeuticsSbi Biotech Co LtdQuark Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgQuark Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationDelayed Graft FunctionHeart Diseases +[5] 

Other Information

ATC CodeN/A
Related LinksN/A